EUVIMEDEUVIMED entdecken
Crossref

Wedelolactone Attenuates Liver Fibrosis and Hepatic Stellate Cell Activation by Suppressing the Hippo Pathway

Wei Zhang, Kai Gao, Ya Bai, Dong Xu, Meina Zhao, Xingru Tao, Jingwen Wang

Rejuvenation Research · 2024-12 · 27 (6) · 207-219

DOI: 10.1089/rej.2024.0053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rejuvenation Research, online erschienen am 06.12.2024. Verfasst von Wei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, YAP-Signaling Proteins, Hippo Signaling Pathway. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a commonly observed pathological phenomenon that occurs during the progression of various types of chronic liver diseases. The Hippo pathway is closely associated with the pathogenesis of liver fibrosis. Previous studies have shown that wedelolactone (WED) has a significant antihepatic fibrosis effect, whereas the target and mechanism underlying WED remain elusive. In this study, we found that WED significantly alleviated liver fibrosis and injury by inhibiting the expression of Yes-associated protein (YAP) and tafazzin (TAZ). In an in vitro model, WED suppressed the activation of hepatic stellate cells (HSCs) induced by transforming growth factor (TGF-β1), as well as the mRNA and protein expression of α-smooth muscle actin (α-SMA), YAP, and TAZ. The allosteric regulation of YAP by WED was confirmed using MD and cellular thermal shift assay. Moreover, specific knockdown or inhibition of YAP did not enhance the suppressive effect of WED on HSC activation or protein expression associated with fibrosis. These findings demonstrated that the administration of WED effectively alleviated liver fibrosis by suppressing the Hippo/YAP/TAZ pathways. In addition, YAP activity may be regulated by WED via allosteric regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsLiver CirrhosisYAP-Signaling ProteinsHippo Signaling PathwaySignal TransductionProtein Serine-Threonine KinasesAnimalsMaleAdaptor Proteins, Signal TransducingAcyltransferasesTranscription FactorsRatsActinsTransforming Growth Factor beta1Rats, Sprague-DawleyHumansCoumarins

Stichwörter der Autor:innen

Hippo pathwayTAZYAPhepatic stellate cellsliver fibrosiswedelolactone

Substanzen

YAP-Signaling ProteinsProtein Serine-Threonine KinaseswedelolactoneAdaptor Proteins, Signal TransducingAcyltransferasesTranscription FactorsYap1 protein, ratActinsTransforming Growth Factor beta1Coumarins

Autor:innen und Institutionen

  • Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.

Zitieren

APA

Zhang, W., Gao, K., Bai, Y., Xu, D., Zhao, M., Tao, X., & Wang, J. (2024). Wedelolactone Attenuates Liver Fibrosis and Hepatic Stellate Cell Activation by Suppressing the Hippo Pathway. Rejuvenation Research, 27(6), 207-219. https://doi.org/10.1089/rej.2024.0053

Vancouver

Zhang W, Gao K, Bai Y, Xu D, Zhao M, Tao X, et al. Wedelolactone Attenuates Liver Fibrosis and Hepatic Stellate Cell Activation by Suppressing the Hippo Pathway. Rejuvenation Research. 2024;27(6):207-219. doi:10.1089/rej.2024.0053

BibTeX
@article{Zhang2024,
  author = {Zhang, Wei and Gao, Kai and Bai, Ya and Xu, Dong and Zhao, Meina and Tao, Xingru and Wang, Jingwen},
  title = {Wedelolactone Attenuates Liver Fibrosis and Hepatic Stellate Cell Activation by Suppressing the Hippo Pathway},
  journal = {Rejuvenation Research},
  year = {2024},
  volume = {27},
  number = {6},
  pages = {207--219},
  doi = {10.1089/rej.2024.0053}
}
Kostenlos starten →